Modulators such as G3BP1 and oncogenic mutations including PIK3CA H1047R further enhance immune resistance by stabilizing PI3K activity or altering immune cell infiltration, while PTEN loss activates PI3Kβ‐driven immune suppression, especially in breast cancer. Here, PIK3CG is linked to breast cancer.